PD-1/PD-L1抑制剂联合曲妥珠单抗在HER2阳性乳腺癌中的研究进展

乳腺癌中有20%~30%的患者表达HER2基因，HER2阳性乳腺癌预后较差，易发生复发和转移。但HER2的表达为乳腺癌治疗提供了新方向。曲妥珠单抗是抗HER2治疗的经典基础药物，然而其原发继发耐药问题引起了大家的注意，研究发现其不敏感及耐药机制的发生可能与肿瘤细胞表面PD-L1上调相关。因此大量关于PD-1/PD-L1抑制剂联合曲妥珠单抗的研究展开意在提高其敏感度，改善其耐药问题。本文就PD-1/PD-L1抑制剂在HER2阳性乳腺癌的临床前及临床研究作一综述。

Research Progress of PD-1/PD-L1 Inhibitor Combined with Trastuzumab in HER2-positive Breast Cancer

HER2 gene is expressed in 20%-30% of breast cancer patients, and HER2 expression provides a new direction for treatment. However, breast cancer with positive HER2 still has a poor prognosis and is prone to recurrence and metastasis. Trastuzumab is a classic basic drug for anti-HER2 therapy. However, the problem of primary and acquired drug resistance of trastuzumab has attracted people's attention. Studies havefound that the occurrence of insensitive and drug resistance mechanism is related to PD-L1 up-regulation on tumor cell surface. Therefore, a large number of studies on PD-1/PD-L1 inhibitor combined with trastuzumab were carried out to improve its sensitivity and drug resistance. This article reviews the preclinical and clinical studies on PD-1/PD-L1 inhibitors in breast cancer with positive HER2.